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We determined prognostic impact of KRAS, BRAF, PIK3CA and TP53 mutation status and mutation heterogeneity among 164
colorectal cancer (CRC) patients undergoing liver resections for metastatic disease. Mutation status was determined by Sanger
sequencing of a total of 422 metastatic deposits. In univariate analysis, KRAS (33.5%), BRAF (6.1%) and PIK3CA (13.4%) muta-
tions each predicted reduced median time to relapse (TTR) (7 vs. 22, 3 vs. 16 and 4 vs. 17 months; p < 0.001, 0.002 and
0.023, respectively). KRAS and BRAF mutations also predicted a reduced median disease-specific survival (DSS) (29 vs. 51 and
16 vs. 49 months; p <0.001 and 0.008, respectively). No effect of TP53 (60.4%) mutation status was observed. Postoperative,
but not preoperative chemotherapy improved both TTR and DSS (p < 0.001 for both) with no interaction with gene mutation
status. Among 94 patients harboring two or more metastatic deposits, 13 revealed mutation heterogeneity across metastatic
deposits for at least one gene. Mutation heterogeneity predicted reduced median DSS compared to homogeneous mutations
(18 vs. 37 months; p 5 0.011 for all genes; 16 vs. 26 months; p < 0.001 analyzing BRAF or KRAS mutations separately). In
multivariate analyses, KRAS or BRAF mutations consistently predicted poor TRR and DSS. Mutation heterogeneity robustly pre-
dicted DSS but not TTR, while postoperative chemotherapy improved both TTR and DSS. Our findings indicate that BRAF and
KRAS mutations as well as mutation heterogeneity predict poor outcome in CRC patients subsequent to liver resections and
might help guide treatment decisions.
Approximately 40% of all patients diagnosed with distant
metastases from colorectal cancer (CRC) have metastatic
deposits confined to the liver.1 Partial liver resection has been
shown to improve long-term survival for selected CRC
patients,2–4 with a 10-year disease-free survival approaching
20% reported even for patients suffering from multiple liver
deposits.3
Selection of patients eligible for surgery has traditionally
been based on clinicopathological prognostic factors.5–7
Recent work, however, has focused on the response to chem-
otherapy and various molecular alterations in the tumor as
more appropriate prognostic factors after liver resections.
Response to neoadjuvant chemotherapy has been related to
improved survival,8 whereas KRAS and BRAF mutations have
been associated with more aggressive disease and a poor
prognosis.9–12 While liver resection for metastatic CRC
(mCRC) has become routine practice,13 the fact that the
majority of patients undergoing surgery subsequently
relapse14 underlines the need for better predictive markers
guiding treatment decisions.
In addition to individual molecular markers, tumor heter-
ogeneity has become a major issue with respect to tumor
evolution and, potentially, therapy outcome. Preliminary
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evidence indicates that clonal evolution may cause acquired
resistance to EGFR blockade.15 Moreover, in a parallel study
in collaboration with others, we found intraindividual hetero-
geneity with respect to copy number alterations to predict
outcome after liver resections (Sveen et al., manuscript sub-
mitted). While several studies have compared genetic altera-
tions between primary tumors and their corresponding
metastatic deposits,16–18 the biological and clinical implica-
tions of intraindividual metastatic heterogeneity remain
poorly understood.
Sampling of multiple synchronous metastatic deposits rep-
resents a challenge in most solid tumors. However, the fact
that liver resections for CRC metastases in general contain
multiple lesions makes this a suitable model for studying
intermetastatic mutation heterogeneity.
The aim of this study was twofold. First, we aimed to
assess the influence of mutations in four major driver genes
(KRAS, BRAF, PIK3CA and TP53) considered as potential
prognostic factors in CRC in patients treated with liver resec-
tions. Second, as genetic heterogeneity may characterize a
distinct tumor phenotype,19 we analyzed gene mutation sta-
tus across multiple metastatic deposits from each patient in
order to determine intraindividual metastatic heterogeneity




Metastatic liver deposits were collected from 164 mCRC
patients undergoing partial liver resection between August
2006 and March 2013. The total number of deposits sampled
and analyzed was 428, including six primary samples and 36
samples collected at re-resections from 23 of these patients.
Seventy-six patients had synchronous while 88 patients
had metachronous liver metastases. Metastases were consid-
ered metachronous if diagnosed 3 months or more after diag-
nosis of the primary tumor.
All patients had a computer tomography (CT) scan per-
formed before surgery. In addition, patients who received
preoperative chemotherapy (n 5 72) had CT scans performed
within 4 weeks before start of chemotherapy and after three
and six treatment cycles to evaluate response to therapy.
The treatment regimen administered most often included
oxaliplatin and fluorouracil, administered as FOLFOX or
Nordic FLOX.2,20 Fourteen patients were treated with irinote-
can before liver resection, and 13 patients were also exposed
to EGFR (seven patients) or VEGF inhibitors (six patients),
12 of these in combination with irinotecan. Fifty-three
patients received chemotherapy after liver resection (postop-
erative chemotherapy).
Response to preoperative chemotherapy was determined
according to the Response Evaluation Criteria in Solid
Tumors (RECIST 1.1).21 Clinical data were retrieved from
electronic patient’s charts. Baseline patient characteristics and
treatment are summarized in Table 1 with further details in
Supporting Information Table S1. The study was approved
by the Regional Ethical Committee, and all patients provided
written informed consent.
Sample collection and evaluation
Following removal, the resected liver specimens were sub-
jected to immediate dissection in the operating theater, and
tissue samples were snap-frozen in liquid nitrogen. In addi-
tion, a small part of each sample was formalin fixed and par-
affin embedded to allow for histopathological confirmation of
tumor cell content. The amount of tumor cells in the whole
section slides was on average 76% (range 10–100%). A total
of 14 samples from ten patients were excluded due to poor
genomic DNA (gDNA) quality and/or a high degree of nor-
mal tissue contamination, leaving samples from 408 metasta-
ses and six primaries available for mutation analysis. For 45
of the patients SNP6 data including ASCAT calculations22 of
the aberrant cell fraction for each sample were also available
(Sveen et al., manuscript submitted).
DNA isolation
Genomic DNA from all patient samples was extracted from
fresh frozen tissue using the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions.
RNA isolation
RNA was extracted from fresh frozen tissue using the RNeasy
Mini Kit (Qiagen), and complimentary DNA (cDNA) was
synthesized using qScript cDNA SuperMix (Quanta, Bio-
Sciences, Gaithersburg, MD), with 320 ng total RNA as
input. Both procedures were performed according to the
manufacturer’s instructions.
What’s new?
Preliminary evidence suggests that poor outcome after liver resection in metastatic colorectal cancer (CRC) is predicted by muta-
tions in KRAS and BRAF and by intra-individual heterogeneity involving copy number alterations that vary from one metastatic
lesion to the next. Little is known, however, about the clinical implications of intra-individual mutation heterogeneity in CRC.
Here, in a comparison of KRAS and BRAF wild-type status, mutational homogeneity, and mutational heterogeneity, mutation het-
erogeneity was found to be the strongest predict or of reduced disease-specific survival following liver resection in metastatic
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DNA preamplification
Genomic DNA from all samples was globally amplified with
a phi29 polymerase using the REPLI-g Midi Kit (Qiagen)
according to the manufacturer’s instructions. In brief, gDNA
was incubated in denaturation buffer for 3 min before addi-
tion of neutralization buffer and a master mix containing
phi29 DNA polymerase with exonuclease proofreading activ-
ity. The isothermal amplification reaction was carried out for
16 hr at 308C.
Mutation screening
BRAF V600 status was analyzed for as previously described.23
KRAS exon 2 (harboring codon 12 and 13) and PIK3CA
exon 9 and 20 were amplified by PCR (detailed in Supporting
Information Methods) and Sanger sequenced. Capillary gel
electrophoresis, data collection and sequence analyses were
performed on an automated ABI 3700 DNA sequencer
(Applied Biosystems, Carlsbad, CA).
Mutation screening was performed on preamplified gDNA
in order to save patient material. All alterations detected
were verified in an independent amplification using original
gDNA as template. For cases with intraindividual heterogene-
ity samples with wild-type results were also reanalyzed using
original gDNA.
TP53 mutation analysis was performed for the whole cod-
ing region of the gene on cDNA from all liver metastatic
deposits as previously described24 (for further details, see
Supporting Information Methods). In short, TP53 was ampli-
fied in a nested PCR and the PCR products were purified
and sequenced on an automated ABI 3700 DNA sequencer
(Applied Biosystems).
All mutations identified were verified by exon-wise
sequencing of gDNA. For cases with intraindividual heteroge-
neity, wild-type results based on cDNA were also reanalyzed
using gDNA.
Statistics
For descriptive statistics we used the mean, median, counts
and proportions (percents). The time to event or censoring
was calculated from the start of treatment for liver metastases
(liver resection or start of preoperative chemotherapy).
Patients dying of causes other than CRC with no evidence of
relapse were treated as censored observations. As for patients
dying subsequent to having a relapse from their CRC, these
patients were considered as dying from CRC unless dying for
reasons obviously unrelated to their CRC.
Unadjusted survival curves for time to relapse (TTR) and
disease-specific survival (DSS) were estimated using the
Kaplan–Meier plot25 and compared between subgroups with
the log-rank test.26
To adjust for possible confounders the Cox proportional
hazards model was applied.27 Due to collinearity multivariate
analyses were performed adjusting for different variables in
the Cox models. In the Supporting Information Tables results
are presented by hazard ratios (HRs) and their 95% confi-
dence intervals (CIs).
All statistical analyses were performed using the SPSS v.22
software. All p-values are given as two-sided.
Results
Mutation frequencies and intraindividual heterogeneity
Overall, the proportions of patients revealing a mutation in
KRAS, BRAF, PIK3CA or TP53 were 33.5, 6.1, 13.4 and
60.4%, respectively. Detailed information on individual muta-
tions is listed in Supporting Information Table S2. As
expected, most of the KRAS mutations detected were point
mutations localized to codons 12 and 13 (104 and 25 sam-
ples, respectively). In addition, we found one insertion
Table 1. Patient characteristics and treatment for 164 metastatic
colorectal cancer patients treated with partial liver resection between
August 2006 and March 2013 at Haukeland University Hospital,
Bergen, Norway
Age (years) at diagnosis, mean (range) 63 (22–83)
Sex (male, female), n 91, 73
Months of follow-up, median (range) 57 (20–98)
Primary tumor site (colon, rectum,
multiple), n
110, 48, 6
Nodal status of primary cancer (pN0,
pN1), n
56, 108
Disease-free interval (months) between
primary and metastases, mean (range)
3 (0–54)
Synchronous or metachronous liver
metastases1, n
76, 88
CEA before liver surgery (<200, >200,
missing), n
108, 15, 41
WHO performance status at start of
treatment (0, I, II, missing), n
102, 58, 3, 1
Number of sampled and analyzed
liver metastases (first liver resection):
-Mean (range) 2 (1–8)
-Patients harboring multiple metastases, n 102
-Patients harboring single metastasis, n 62
Chemotherapy exposure:
-Adjuvant chemotherapy (primary setting),
n
26
-Chemotherapy before liver resection2, n 72
-Chemotherapy after liver resection (post-
operative chemotherapy)
53
Best response on chemotherapy (CR, PR,
SD)3, n
1, 41, 28
1Metastases were considered metachronous if diagnosed 3 months
after diagnosis of the primary tumor.
2Three courses of treatment (except three patients who had to stop
treatment after one or two cycles, due to side effects).
3Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Not calcu-
lated for the patients receiving only one treatment course.
Abbreviations: CEA: carcinoembryonic antigen; CR: complete response;
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between these two codons in two samples and a point muta-
tion localized at codon 19 in one sample. All but two of the
BRAF-mutated samples harbored the V600E mutation. All
PIK3CA mutations were point mutations, the most frequent
ones being E542K and E545K in exon 9. As for TP53, 226
and 27 samples harbored point mutations and indels, respec-
tively. Notably, in five of the patients more than one TP53
mutation was detected in each mutated sample, and for one
patient the second TP53 mutation was found in one out of
three metastases only.
Among 94 patients from whom two or more metastatic
deposits collected at the same resection were examined, 13
patients revealed mutation heterogeneity for at least one of
the four genes examined across their metastatic deposits (Fig.
1). For each individual gene, the number of patients revealing
heterogeneous mutation results for KRAS, BRAF, PIK3CA
and TP53 was 10, 1, 5 and 9, respectively. Notably, in five
patients, KRAS or TP53 mutations seemed to evolve over
time either between the primary and the metastases or
between the first and second liver resection (see details in
Supporting Information Table S2).
Mutation frequencies in subgroups of patients with differ-
ent chemotherapy exposure are listed in Supporting Informa-
tion Table S3.
Figure 1. Intraindividual heterogeneity between liver metastases as determined by different mutation status for one or more of the genes
TP53, KRAS, BRAF and PIK3CA. Each row represents one patient. Each circle represents a metastatic sample harvested at the first liver sur-
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Mutation status and prognosis after liver resection
To evaluate the prognostic impact of the mutations described
above in patients treated with liver resections, we excluded
patients who had undergone a previous liver resection
(n 5 13) before inclusion in the present study, leaving a total
of 151 patients.
In univariate analyses (Fig. 2), we found KRAS and BRAF
mutations both to be associated with reduced median TTR (7
vs. 22 and 3 vs. 16 months; p< 0.001 and p 5 0.002, respec-
tively) and reduced median DSS (29 vs. 51 and 16 vs. 49
months; p 5 0.008 and p< 0.001, respectively). Because KRAS
and BRAF mutations are known to be mutually exclusive,28,29
we performed a combined analysis in addition (Fig. 2).
Patients harboring either a KRAS or a BRAF mutation
revealed an inferior median TTR (7 vs. 24 months) as well as
DSS (26 vs. 56 months, p< 0.001 for both comparisons)
compared to patients with deposits wild-type for both genes.
Mutations in PIK3CA were associated with a reduced TTR (4
vs. 17 months; p 5 0.023), but not with reduced DSS, while
TP53 mutation status revealed no significant relation to either
TTR or DSS. Considering the number of metastatic deposits,
patients with multiple liver deposits had a somewhat shorter
TTR compared to patients with one deposit only (p 5 0.008)
while no significant effect on DSS was recorded (Supporting
Information Table S4).
Interestingly, KRAS mutations seemed to be associated
with a shorter median TTR in patients harboring synchro-
nous (p 5 0.002) as well as metachronous (p 5 0.019) disease,
but with DSS only in synchronous disease (p 5 0.001; Sup-
porting Information Fig. S1a). Similar findings were observed
for KRAS and BRAF mutations combined (Supporting Infor-
mation Fig. S1b).
Influence of chemotherapy exposure
Among the 151 patients, 33 patients received preoperative
chemotherapy only, 17 patients had chemotherapy after sur-
gery only, 36 patients received both presurgical and postsur-
gical chemotherapy, while 65 patients received no
chemotherapy neither before nor after their liver surgery.
Comparing all the four treatment groups together, a signifi-
cant effect on TRR (p< 0.001) as well as DSS (p 5 0.001)
was recorded, with a clear preference for postoperative chem-
otherapy (Fig. 3). Analyzing separately for preoperative or
postoperative therapy as variables in univariate analysis,
interestingly postoperative therapy influenced TTR as well as
DSS for the total group of patients (p< 0.001 for both)
(Fig. 3), while presurgical chemotherapy improved TTR
among patients harboring a KRAS mutation only (Supporting
Information Figs. S2c and S2d; p 5 0.018). However, except
for a weak interaction between KRAS and BRAF wild-type
status and benefit from preoperative chemotherapy
(p 5 0.02), no statistically significant interaction between
mutation status for any of the genes analyzed and benefit
from chemotherapy administered in the preoperative or post-
operative setting was recorded (Supporting Information Figs.
S2 and S3). Notably chemotherapy response (partial response
vs. stable disease) per se did not influence survival after liver
resection in our dataset (Supporting Information Table S4);
neither did we observe any difference in TTR or DSS
between patients commencing postsurgical chemotherapy
within a time frame of 4 weeks vs. patients commencing on
chemotherapy later than 4 weeks after surgery (Supporting
Information Fig. S4).
Figure 2. Kaplan–Meier survival curves illustrating time to relapse
(left panels) and disease-specific survival (right panels) after liver
surgery for metastatic colorectal cancer with respect to mutation
status for KRAS, BRAF, KRAS and BRAF combined, PIK3CA and TP53
(n 5 151 in each panel). A patient was classified as harboring a
gene mutation as long as it was present in at least one lesion. p-
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Figure 3. Kaplan–Meier survival curves illustrating differences in time to relapse (left panels) and disease-specific survival (right panels)
after liver surgery for metastatic colorectal cancer, based on chemotherapy regimens administered at different times in relation to liver sur-
gery. p-values are from log-rank tests. (a) All four treatment groups presented. (b) All patients receiving preoperative chemotherapy (alone
or combined with postoperative chemotherapy) vs. patients receiving no preoperative chemotherapy (with or without postoperative chemo-
therapy). (c) Patients receiving postoperative chemotherapy (alone or in concert with preoperative therapy) vs. patients receiving no postop-
erative chemotherapy (with or without preoperative chemotherapy). (d) All patients receiving chemotherapy for liver metastases at any time
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Mutation heterogeneity and prognosis after liver resection
The potential impact of mutation heterogeneity (defined as
different mutation status between metastases harvested from
the same patient at the same surgical procedure) on outcome
was evaluated in the subgroup of patient harboring two or
more liver deposits (n 5 94).
First, we confirmed the prognostic impact of KRAS, BRAF
and PI3K mutation status revealed in the total patient cohort in
the subgroup of patients harboring multiple deposits (Support-
ing Information Table S5). Next, we compared outcome
between (i) patients with mutation heterogeneity affecting either
KRAS, BRAF, PI3K or TP53 across metastatic deposits (n 5 13),
(ii) patients harboring a homogeneous mutation in at least one
gene across all metastatic deposits and with no heterogeneous
mutation and (iii) patients with no mutations across either
gene. Comparing all three groups, univariate analysis revealed a
significant different TTR (median of 4 vs. 5 vs. 15 months,
p< 0.001) as well as DSS (median of 18 vs. 37 vs. 58 months,
p< 0.001) between the groups (Fig. 4a). Notably, the difference
in DSS between patients in Group 1 (harboring heterogeneous
mutation) vs. patients in Group 2 (harboring homogeneous
mutations only), 18 vs. 37 months, was of statistical significance
(p 5 0.011). Similar analysis restricted to patients being (i) het-
erogeneous vs. (ii) homogeneous for BRAF or KRAS mutations
or (iii) wild type for both genes revealed similar results (median
DSS of 16, vs. 26 vs. 49 months, p< 0.001 comparing all three
groups; p< 0.035 comparing patients heterogeneous vs. homog-
enous for BRAF and KRAS mutations; Fig. 4b).
Multivariate analyses
As KRAS and BRAF mutations were mutually exclusive, these
parameters (BRAF or KRAS mutation vs. wild-type status for
Figure 4. Kaplan–Meier survival curves illustrating differences in time to relapse (left panels) and disease-specific survival (right panels)
after liver surgery for metastatic colorectal cancer comparing patients harboring no mutations to patients harboring intraindividual mutation
heterogeneity across either KRAS, BRAF, TP53 or PI3K and patients revealing at least one homogenous but no heterogeneous mutation in
either gene (a). Similar analyses comparing patients harboring no mutations, heterogeneous or homogeneous mutations in either KRAS or
BRAF without attention to TP53 or PI3K status (b). p-values are from log-rank tests. p-values relate to comparison between all three groups.
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both) were combined into one parameter for the multivariate
analyses. In addition, as the use of different treatment regi-
mens depended on stage of disease (meta- vs. synchronous
metastases, nodal status of the primary) as well as previous
therapy, repeated multivariate analyses were performed enter-
ing different variables into the models.
The detailed results of these analyses are summarized in
Table 2 and Supporting Information Table S6. For the total
cohort (n 5 151) as well as for the subcohort harboring mul-
tiple metastatic deposits (n 5 94), mutations affecting KRAS
or BRAF in a homogeneous or heterogeneous manner consis-
tently predicted a poor TRR as well as a poor DSS across all
models. In addition, postoperative chemotherapy (with or
without prior preoperative therapy) improved TTR as well as
DSS. Notably, in the subgroup of patients with multiple
deposits (n 5 94), mutation heterogeneity independently pre-
dicted DSS but not TTR across models (Supporting Informa-
tion Table S6).
Discussion
Liver resections improve outcome in CRC patients harboring
liver metastases, and some patients become long-term survi-
vors.3,4 It represents a major surgical intervention however,
and the fact that many patients only gain limited benefit14
calls for identification of improved prognostic and predictive
factors.5
The aim of this study was twofold; first, we assessed the
influence of mutations in four key driver genes (KRAS,
BRAF, PIK3CA and TP53) determined on metastatic deposits
on outcome after liver resections for CRC. Second, we ana-
lyzed gene mutation status across multiple deposits from
each patient in order to determine intraindividual mutation
heterogeneity and its potential impact on prognosis.
The frequencies of KRAS, PIK3CA and TP53 mutations
resemble what has been detected by others in metastatic liver
deposits, but for BRAF the incidence was slightly higher than
in most other series analyzing liver metastases.16,30–32 While
previous studies have revealed BRAF mutations to be associ-
ated with a poor outcome following liver resection for
CRC,11,12 the results for KRAS mutation have been at
variance.9,32,33
Here, BRAF as well as KRAS mutation status (each one
individually as well as combined) was associated with a poor
prognosis in univariate analysis in the total patient cohort as
well as in the subgroup of patients harboring multiple liver
deposits. Moreover, both mutations consistently predicted a
poor outcome across different multivariate models. Consider-
ing PI3KCA and TP53 mutation status, conflicting results
have linked mutations in these genes to outcome in CRC
patients.34–38 Here, we found PI3KCA mutations to be associ-
ated only with a reduced TTR but not DSS in univariate
analysis; in contrast, no association between TP53 mutation
status and outcome (either TTR or DSS) was recorded.
Chemotherapy administered in relation to liver resections
has been reported to improve TTR but not DSS.2 Patients
included in this study were selected for chemotherapy based
on demographic and medical conditions including age, gen-
eral health condition and previously chemotherapy expo-
sure.39 The fact that chemotherapy was not administered in a
randomized setting means that the results need to be inter-
preted carefully. Our finding that postoperative but not pre-
operative chemotherapy seems to be of significant benefit
however is of interest. If confirmed in independent studies,
this will have clinical implications. This observation contrasts
results obtained with use of primary medical therapy (neoad-
juvant chemotherapy) in other cancer forms like breast can-
cer.40 However, liver resection normally is followed by a
rapid liver tissue regeneration, to be accompanied by secre-
tion of multiple growth factors.41 This setting may have det-
rimental effects on subclinical metastatic deposits, offering a
potential explanation for a particular benefit of chemotherapy
treatment during this time period. The finding of no
Table 2. Results from Cox regression for all patients (n 5 151)
Time to relapse (TTR) Disease-specific survival (DSS)
HR 95% CI p values HR 95% CI p values
Age (< or > 65 years) 1.08 (0.71, 1.65) 0.720 0.72 (0.45, 1.17) 0.183
Sex (male vs. female) 0.93 (0.62, 1.40) 0.726 0.98 (0.62, 1.57) 0.942
Nodal status of primary (N1 vs. N0) 1.55 (0.97, 2.48) 0.064 1.99 (1.13, 3.53) 0.018
Synchronous vs. metachronous mets. 2.00 (1.21, 3.29) 0.007 1.58 (0.90, 2.77) 0.110
Multiple vs. single mets. 1.73 (1.11, 2.68) 0.015 1.55 (0.93, 2.58) 0.095
TP53 mutations 0.92 (0.61,1.42) 0.720 0.78 (0.47,1.28) 0.318
PIK3CA mutations 1.12 (0.63, 1.97) 0.700 0.78 (0.40, 1.51) 0.451
KRAS or BRAF mutations
(mut vs. double wt)
2.34 (1.50, 3.66) <0.001 2.47 (1.49, 4.10) <0.001
Chemotherapy1 0.39 (0.23, 0.64) <0.001 0.46 (0.26, 0.80) 0.005
p-values are from the first step of the likelihood ratio (LR) test. Bold indicates significant p-values.
1Administered before surgery, after surgery or both.
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interaction (except for a weak association between KRAS and
BRAF wild-type status and benefit from preoperative therapy)
between gene mutation status and mutation heterogeneity on
the one hand and benefit from chemotherapy on the other
hand further supports a prognostic role of these mutations,
suggesting mechanisms related to tumor cell growth, inva-
sion, metastatic propensity and others and not resistance to
chemotherapy to explain our observations.
Heterogeneity within primary tumors is well recognized as
an important challenge to personalized medicine19,42–45
Recent studies have revealed clonal heterogeneity for KRAS
mutations within primary CRCs,46,47 and several studies have
examined concordance in mutation status between primary
tumors and metastatic deposits.16–18 Mutation heterogeneity
across synchronous deposits, however, is not well described.
We observed heterogeneous mutation results in respect to
the four driver genes analyzed in 13 of 94 patients (12.2%)
harboring multiple liver deposits. Comparing DSS between
tumors revealing a heterogeneous mutation affecting any of
the four genes analyzed and tumors harboring a homozygous
mutation for one (or more) of these genes revealed an infe-
rior DSS for tumors harboring heterogeneous mutations.
Notably, mutation heterogeneity was found to be an inde-
pendent prognostic factor in multivariate analysis.
Ten patients harbored a heterogeneous KRAS mutation,
and one revealed a heterogeneous BRAF mutation. Similar to
what was recorded in respect to mutation heterogeneity
across all four genes analyzed, mutation heterogeneity for
BRAF or KRAS revealed an inferior prognosis as compared
to homozygous mutations across the two genes. While we
may not exclude the possibility that heterogeneity for BRAF
and KRAS mutations could explain the findings obtained in
respect to heterogeneity across all four genes, our findings in
metastatic CRC are consistent with observations by others
revealing tumor heterogeneity to predict a poor prognosis
across different forms of primary solid tumors.48–50
In conclusion, we confirmed KRAS and BRAF mutations
to be a robust prognostic parameter in patients treated with
partial liver resections for metastatic CRC. These findings
indicate that KRAS/BRAF mutation status should be taken
into account together with other prognostic parameters when
selecting patients for surgery. Second, our results point to an
important role of postsurgical but probably not presurgical
chemotherapy in relation to liver resections; confirmation in
independent studies is warranted. Finally, our data support
the hypothesis that mutation heterogeneity could be a marker
associated with an aggressive clinical behavior. If confirmed
by others, these findings may be of importance to patient
treatment and also improve our understanding of the clinical
and biological importance of mutation heterogeneity in meta-
static disease.
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